to offer rapid genome sequencing in standard care to all seriously ill children in the future." SERVICE: For more information , contact Dr. Bernd Auber, auber.bernd@mh-hannover.de , phone (0511) 532-8719

there could be many more transport jobs waiting for the MLIV.K and MLIV.A gene taxis in the future. SERVICE: For further information , please contact Professor Dr Hildegard Büning, buening.hildegard@mh-hannover

case of chronically progressive, often therapy-resistant pulmonary arterial hypertension (PAH). SERVICE For further information , please contact Professor Dr. Georg Hansmann, telephone (0511) 532-9594

approaches for both causes of cardiac injury, for which there is currently no specific treatment. SERVICE: For further information , please contact Professor Dr. Dr. Thomas Thum, thum.thomas@mh-hannover

s have already filed a patent application for the use of MYGDF as a new drug for heart failure. SERVICE: For further information , please contact Professor Dr. Kai Wollert, wollert.kai@mh-hannover.de

database of disease cases and collects biomaterial from affected individuals for scientific studies. SERVICE: The original paper can be found here .

confirmed in further studies in large animal models and later also in clinical studies in humans. SERVICE: For further information, please contact Dr. Christian Bär, baer.christian@mh-hannover.de , phone

after which initial results are expected. German Cancer Aid is funding the study with 750,000 euros. SERVICE: For further information, please contact PD Dr. med. Matthias Jentschke, Jentschke.Matthias@mh-hannover

Research and by the Canadian Institutes of Health Research and the Terry Fox Research Institute. SERVICE: For further information , please contact Professor Dr. Christian Kratz, telephone + 49 (511) 532-6712

within the framework of the Lung Ambition Alliance, a partnership between industry and science. SERVICE: For more information , please contact Professor Dr Jens Vogel-Claussen, scientific director of the